Medical Oncology, Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, 34300 Istanbul, Turkey.
World J Gastroenterol. 2013;19(14):2154-61. doi: 10.3748/wjg.v19.i14.2154.
To evaluate the location, histopathology, stages, and treatment of gastric cancer and to conduct survival analysis on prognostic factors.
Patients diagnosed with of stomach cancer in our clinic between 2000 and 2011, with follow-up or a treatment decision, were evaluated retrospectively. They were followed up by no treatment, adjuvant therapy, or metastatic therapy. We excluded from the study any patients whose laboratory records lacked the operating parameters. The type of surgery in patients diagnosed with gastric cancer was total gastrectomy, subtotal gastrectomy or palliative surgery. Patients with indications for adjuvant treatment were treated with adjuvant and/or radio-chemotherapy. Prognostic evaluation was made based on the parameters of the patient, tumor and treatment.
In this study, outpatient clinic records of patients with gastric cancer diagnosis were analyzed retrospectively. A total of 796 patients were evaluated (552 male, 244 female). The median age was 58 years (22-90 years). The median follow-up period was 12 mo (1-276 mo), and median survival time was 12 mo (11.5-12.4 mo). Increased T stage and N stage resulted in a decrease in survival. Other prognostic factors related to the disease were positive surgical margins, lymphovascular invasion, perineural invasion, cardio-esophageal settlement, and the levels of tumor markers in metastatic disease. No prognostic significance of the patient's age, sex or tumor histopathology was detected.
The prognostic factors identified in all groups and the proposed treatments according to stage should be applied, and innovations in the new targeted therapies should be followed.
评估胃癌的位置、组织病理学、分期和治疗方法，并对预后因素进行生存分析。
回顾性评估 2000 年至 2011 年间在我们诊所诊断为胃癌的患者，这些患者有随访或治疗决策。他们未接受治疗、辅助治疗或转移性治疗。我们排除了任何实验室记录缺乏手术参数的患者。诊断为胃癌的患者的手术类型为全胃切除术、胃次全切除术或姑息性手术。有辅助治疗指征的患者接受辅助和/或放化疗。根据患者、肿瘤和治疗的参数进行预后评估。
本研究回顾性分析了胃癌患者的门诊病历。共评估了 796 例患者（552 例男性，244 例女性）。中位年龄为 58 岁（22-90 岁）。中位随访时间为 12 个月（1-276 个月），中位生存时间为 12 个月（11.5-12.4 个月）。T 分期和 N 分期的增加导致生存时间缩短。其他与疾病相关的预后因素包括阳性手术切缘、淋巴血管侵犯、神经周围侵犯、心食管转移和转移性疾病中肿瘤标志物的水平。患者的年龄、性别或肿瘤组织病理学与预后无关。
应根据所有组别的预后因素和分期提出的治疗方法，并应关注新的靶向治疗方法的创新。
